Search

Your search keyword '"de Bruin‐Weller, Marjolein S."' showing total 397 results
Start Over Author "de Bruin‐Weller, Marjolein S."
397 results on '"de Bruin‐Weller, Marjolein S."'

1. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Author

Simpson, Eric L., Prajapati, Vimal H., Leshem, Yael A., Chovatiya, Raj, de Bruin-Weller, Marjolein S., Ständer, Sonja, Pink, Andrew E., Calimlim, Brian M., Lee, Wan-Ju, Teixeira, Henrique, Ladizinski, Barry, Hu, Xiaofei, Yang, Yang, Liu, Yingyi, Liu, Meng, Grada, Ayman, Platt, Andrew M., and Silverberg, Jonathan I.

Published
2024
Full Text
View/download PDF

2. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, Fernández-Orland, Almudena, Warren, Richard B, Agner, Tove, Schuttelaar, Marie L A, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, and Strange Vest, Natacha

Published
2024
Full Text
View/download PDF

3. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry

Author

Zhang, Junfen, Boesjes, Celeste M., Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L.E., Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Dekkers, Coco C., van der Rijst, Lisa P., Oosting, Albert J., van Lumig, Paula, van Lynden-van Nes, Anneke M.T., Tupker, Ron A., Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R.H., Christoffers, Wianda A., Stewart, Shiarra M., Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S., and Schuttelaar, Marie-Louise A.

Published
2024
Full Text
View/download PDF

7. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Author

Ariëns, Lieneke F.M., van der Schaft, Jorien, Spekhorst, Lotte S., Bakker, Daphne S., Romeijn, Geertruida L.E., Kouwenhoven, Tessa A., Kamsteeg, Marijke, Voorberg, Angelique N., Oosting, Albert J., de Ridder, Ilona, Sloeserwij, Annemieke, Haeck, Inge, Thijs, Judith L., Schuttelaar, Marie L.A., and de Bruin-Weller, Marjolein S.

Published
2021
Full Text
View/download PDF

8. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis

Author

Boesjes, Celeste M., Kamphuis, Esmé, de Graaf, Marlies, Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Loman, Laura, Zuithoff, Nicolaas P. A., Dekkers, Coco, van der Rijst, Lisa P., Romeijn, Geertruida L. E., Oosting, Albert J., Gostynksi, Antoni, van Lynden-van Nes, Anneke M. T., Tupker, Ron A., van Tuyll van Serooskerken, Anne-Moon, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R. H., Christoffers, Wianda A., Stewart, Shiarra M., Kamsteeg, Marijke, Schuttelaar, Marie-Louise A., and de Bruin-Weller, Marjolein S.

Abstract

IMPORTANCE: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. OBJECTIVE: To evaluate clinical effectiveness and reasons for discontinuation of dupilumab treatment in children, adults, and older adults with AD with up to 5 years of treatment in daily practice. DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter cohort study was conducted using the BioDay registry (4 academic and 10 nonacademic hospitals in the Netherlands) to identify patients with AD of all ages who were treated with dupilumab between October 2017 and December 2022. MAIN OUTCOMES AND MEASURES: Clinical effectiveness was evaluated by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and numeric rating scale (NRS) for pruritus, stratified by children (<18 years), adults (18-64 years), and older adults (≥65 years). In addition, time to response, treatment responders, EASI subscores, second treatment episodes, and thymus- and activation-related chemokine and eosinophil levels were assessed. For patients who discontinued dupilumab, the reason for discontinuation was evaluated. RESULTS: In total, 1286 patients with AD (median [IQR] age, 38 [26-54] years; 726 [56.6%] male) were treated with dupilumab, including 130 children, 1025 adults, and 131 older adults. The median (IQR) follow-up time was 87.5 (32.0-157.0) weeks. Most patients maintained controlled AD, with EASI of 7 or lower and NRS for pruritus of 4 or lower varying between 78.6% and 92.3% and 72.2% and 88.2% for up to 5 years of treatment, respectively, while up to 70.5% of all patients prolonged the dosing interval to mostly 300 mg every 3 or 4 weeks. Mean EASI and NRS for pruritus were 2.7 (95% CI, 1.2-4.2) and 3.5 (95% CI, 2.7-4.3), respectively, after 5 years of treatment. Statistically significant differences between age groups were found over time for EASI and IGA; however, differences were rather small (week 52: EASI, 0.3-1.6; IGA, 0.12-0.26). No statistically significant differences between age groups were found for NRS for pruritus. Median thymus- and activation-related chemokine levels considerably decreased from 1751 pg/mL (95% CI, 1614-1900 pg/mL) to 390 pg/mL (95% CI, 368-413 pg/mL) after 6 months of treatment and remained low. Median eosinophil levels temporarily increased up to week 16, with a subsequently statistically significant decrease over time. In total, 306 patients (23.8%) discontinued dupilumab after a median (IQR) of 54.0 (29.0-110.00) weeks, with adverse events among 98 patients (7.6%) and ineffectiveness among 85 patients (6.6%) as the most frequently reported reasons. Forty-one patients (3.2%) restarted dupilumab, and most of these patients recaptured response. CONCLUSIONS AND RELEVANCE: In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. Treatment was discontinued in 23.8% of patients mainly due to adverse events and/or ineffectiveness.

Published
2024
Full Text
View/download PDF

9. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Author

Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, Zhang, Junfen, Boesjes, Celeste M, Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L E, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Dekkers, Coco C, van der Rijst, Lisa P, Oosting, Albert J, van Lumig, Paula, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise A, Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, Zhang, Junfen, Boesjes, Celeste M, Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L E, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Dekkers, Coco C, van der Rijst, Lisa P, Oosting, Albert J, van Lumig, Paula, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie-Louise A

Published
2024

10. Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry

Author

Infection & Immunity, MS Dermatologie/Allergologie, CTM & Statistical consultation, Other research (not in main researchprogram), Rijst, Lisa P van der, Groot, Karin M de Winter-de, Zuithoff, Nicolaas P A, de Bruin-Weller, Marjolein S, de Graaf, Marlies, Infection & Immunity, MS Dermatologie/Allergologie, CTM & Statistical consultation, Other research (not in main researchprogram), Rijst, Lisa P van der, Groot, Karin M de Winter-de, Zuithoff, Nicolaas P A, de Bruin-Weller, Marjolein S, and de Graaf, Marlies

Published
2024

11. Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Research, CTI Van Wijk, Child Health, Boesjes, Celeste M, Bakker, Daphne S, Knol, Edward F, de Graaf, Marlies, van Wijk, Femke, de Bruin-Weller, Marjolein S, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Research, CTI Van Wijk, Child Health, Boesjes, Celeste M, Bakker, Daphne S, Knol, Edward F, de Graaf, Marlies, van Wijk, Femke, and de Bruin-Weller, Marjolein S

Published
2024

12. Reply to Sujoy Khan

Author

MS Dermatologie/Allergologie, Infection & Immunity, Longziekten patientenzorg, Child Health, van der Rijst, Lisa P, de Winter-de Groot, Karin M, de Bruin-Weller, Marjolein S, de Graaf, Marlies, MS Dermatologie/Allergologie, Infection & Immunity, Longziekten patientenzorg, Child Health, van der Rijst, Lisa P, de Winter-de Groot, Karin M, de Bruin-Weller, Marjolein S, and de Graaf, Marlies

Published
2024

13. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Author

MS Dermatologie/Allergologie, Infection & Immunity, Simpson, Eric L., Prajapati, Vimal H., Leshem, Yael A., Chovatiya, Raj, de Bruin-Weller, Marjolein S., Ständer, Sonja, Pink, Andrew E., Calimlim, Brian M., Lee, Wan Ju, Teixeira, Henrique, Ladizinski, Barry, Hu, Xiaofei, Yang, Yang, Liu, Yingyi, Liu, Meng, Grada, Ayman, Platt, Andrew M., Silverberg, Jonathan I., MS Dermatologie/Allergologie, Infection & Immunity, Simpson, Eric L., Prajapati, Vimal H., Leshem, Yael A., Chovatiya, Raj, de Bruin-Weller, Marjolein S., Ständer, Sonja, Pink, Andrew E., Calimlim, Brian M., Lee, Wan Ju, Teixeira, Henrique, Ladizinski, Barry, Hu, Xiaofei, Yang, Yang, Liu, Yingyi, Liu, Meng, Grada, Ayman, Platt, Andrew M., and Silverberg, Jonathan I.

Published
2024

14. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Kamphuis, Esmé, Boesjes, Celeste M, Loman, Laura, Kamsteeg, Marijke, Haeck, Inge, Van Lynden-van Nes, Anneke M T, Politiek, Klaziena, Van der Gang, Liana F, De Graaf, Marlies, De Bruin-Weller, Marjolein S, Schuttelaar, Marie L A, MS Dermatologie/Allergologie, Infection & Immunity, Kamphuis, Esmé, Boesjes, Celeste M, Loman, Laura, Kamsteeg, Marijke, Haeck, Inge, Van Lynden-van Nes, Anneke M T, Politiek, Klaziena, Van der Gang, Liana F, De Graaf, Marlies, De Bruin-Weller, Marjolein S, and Schuttelaar, Marie L A

Published
2024

15. Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients.

Author

van der Rijst, Lisa P., Hilbrands, Michelle S., Zuithoff, Nicolaas P. A., de Bruin‐Weller, Marjolein S., Knulst, André C., Le, Thuy‐My, and de Graaf, Marlies

Subjects
IMMUNOGLOBULIN E, ATOPIC dermatitis, DUPILUMAB, ALMOND, FOOD allergy, IMMUNOGLOBULIN class switching, NATURAL history
Abstract

This article explores the impact of dupilumab, a monoclonal antibody used to treat atopic dermatitis, on food-specific immunoglobulin E (sIgE) levels in pediatric patients with moderate to severe atopic dermatitis. The study found that dupilumab led to a significant decrease in sIgE levels for various food allergens in these patients. This research is valuable for understanding the potential benefits of dupilumab in treating food allergies in young patients with atopic dermatitis. However, more research is needed to fully comprehend the effects of dupilumab in pediatric patients. [Extracted from the article]

Published
2024
Full Text
View/download PDF

16. Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry.

Author

Rijst, Lisa P. van der, Groot, Karin M. de Winter‐de, Zuithoff, Nicolaas P. A., de Bruin‐Weller, Marjolein S., and de Graaf, Marlies

Subjects
ATOPIC dermatitis, DUPILUMAB, FORCED expiratory volume, ASTHMA, ATOPY, ASTHMATICS, VOCAL cord dysfunction
Abstract

Background: Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited. Objective: To investigate the prevalence of asthma and AR in pediatric AD patients starting dupilumab treatment and to evaluate the effect of dupilumab on these comorbidities. Methods: This study included pediatric AD patients (aged 3–17 years) treated with dupilumab between 2019 and 2023. Patients were screened at baseline by a pulmonologist for the presence of asthma and AR. Screening included evaluation of medical history and current symptoms, spirometry (including Forced Expiratory Volume in 1 s (FEV1)), Fractional exhaled Nitric Oxide (FeNO), and measurement of aeroallergen‐specific IgE levels. In patients diagnosed with comorbid asthma and/or AR, measurements were repeated at weeks 16 and 52. Spirometry measurements, FeNO, and aeroallergen‐specific IgE levels during treatment were analyzed using a covariance pattern model. Results: Eighty‐four patients were included. Asthma was diagnosed in 50 patients (59.5%) and AR in 72 patients (85.7%). Baseline FeNO levels were elevated in both patients with (29.0 ppb (95% CI 22.0–54.0)) and without asthma (26.0 ppb (95% CI 22.0–30.0)). During treatment, FeNO levels decreased (p <.001) and FEV1 scores increased (p <.001) in patients with asthma. In patients with asthma and/or AR, all aeroallergen‐specific IgE levels decreased between 61.3% and 89.1% at 52 weeks of treatment. Conclusion: One year of dupilumab treatment, primarily indicated for AD, resulted in a significant improvement in comorbid asthma and a profound decrease in aeroallergen‐specific IgE levels in patients with asthma and/or AR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Author

Kamphuis, Esmé, primary, Boesjes, Celeste M., additional, Loman, Laura, additional, Kamsteeg, Marijke, additional, Haeck, Inge, additional, Van Lynden-van Nes, Anneke M.T., additional, Politiek, Klaziena, additional, Van der Gang, Liana F., additional, De Graaf, Marlies, additional, De Bruin-Weller, Marjolein S., additional, and Schuttelaar, Marie L.A., additional

Published
2024
Full Text
View/download PDF

18. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Bissonnette, Robert, Warren, Richard B, Pinter, Andreas, Agner, Tove, Gooderham, Melinda, Schuttelaar, Marie L A, Crépy, Marie-Noëlle, Stingeni, Luca, Serra-Baldrich, Esther, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, Strange Vest, Natacha, Schliemann, Sibylle, Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, and Fernández-Orland, Almudena

Abstract

Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema.

Published
2024
Full Text
View/download PDF

22. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

Author

Spekhorst, Lotte S, primary, Boesjes, Celeste M, additional, Loman, Laura, additional, Zuithoff, Nicolaas P A, additional, Bakker, Daphne S, additional, Kamphuis, Esmé, additional, Kamsteeg, Marijke, additional, Haeck, Inge M, additional, Oosting, Albert J, additional, van Lumig, Paula P M, additional, van Lynden-van Nes, Anneke M T, additional, Tupker, Ron A, additional, Flinterman, Annebeth, additional, Garritsen, Floor M, additional, Touwslager, Wouter R H, additional, de Bruin-Weller, Marjolein S, additional, Schuttelaar, Marie-Louise A, additional, and de Graaf, Marlies, additional

Published
2023
Full Text
View/download PDF

23. Biologicals for pediatric patients with atopic dermatitis:practical challenges and knowledge gaps

Author

van der Rijst, Lisa P., van Royen-Kerkhof, Annet, Pasmans, Suzanne G.M.A., Schappin, Renske, de Bruin-Weller, Marjolein S., de Graaf, Marlies, van der Rijst, Lisa P., van Royen-Kerkhof, Annet, Pasmans, Suzanne G.M.A., Schappin, Renske, de Bruin-Weller, Marjolein S., and de Graaf, Marlies

Abstract

Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab was the first biological registered for AD in pediatric patients and was recently approved for patients aged six months to five years. Current and emerging biologicals may address the unmet need for effective and safe treatment options for pediatric AD patients, however, little is known about the practical implementation of biologicals in infants and preschoolers (aged <6 years), including the timing of treatment initiation, discontinuation, and long-term administration of the subcutaneous injections. Currently, only a small number of biologicals are approved for the treatment of infants and preschoolers for other inflammatory diseases. Consequently, data on the practical implementation of biological treatment remain scarce. In addition, long-term effects, impact on co-morbidities, and impact on live-accentuated vaccination are still unknown. With the introduction of biologicals for AD from the age of six months, potential challenges within the implementation of biologicals may arise. Therefore, we aim to discuss current practical challenges and knowledge gaps of the treatment with biologicals in infants and preschoolers with AD.

Published
2023

24. Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Geneeskunde, Pathologie Pathologen staf, Cancer, Boesjes, Celeste M, van der Gang, Lian F, Bakker, Daphne S, Ten Cate, Tess A, Spekhorst, Lotte S, de Graaf, Marlies, van Dijk, Marijke R, de Bruin-Weller, Marjolein S, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Geneeskunde, Pathologie Pathologen staf, Cancer, Boesjes, Celeste M, van der Gang, Lian F, Bakker, Daphne S, Ten Cate, Tess A, Spekhorst, Lotte S, de Graaf, Marlies, van Dijk, Marijke R, and de Bruin-Weller, Marjolein S

Published
2023

25. Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps

Author

MS Dermatologie/Allergologie, Infection & Immunity, Geneeskunde, Immuno/reuma patientenzorg, Child Health, van der Rijst, Lisa P., van Royen-Kerkhof, Annet, Pasmans, Suzanne G.M.A., Schappin, Renske, de Bruin-Weller, Marjolein S., de Graaf, Marlies, MS Dermatologie/Allergologie, Infection & Immunity, Geneeskunde, Immuno/reuma patientenzorg, Child Health, van der Rijst, Lisa P., van Royen-Kerkhof, Annet, Pasmans, Suzanne G.M.A., Schappin, Renske, de Bruin-Weller, Marjolein S., and de Graaf, Marlies

Published
2023

26. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Spekhorst, Lotte S, Boesjes, Celeste M, Loman, Laura, Zuithoff, Nicolaas P A, Bakker, Daphne S, Kamphuis, Esmé, Kamsteeg, Marijke, Haeck, Inge, Oosting, Albert J, van Lumig, Paula P M, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Flinterman, Annebeth, Garritsen, Floor M, Touwslager, Wouter R H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, de Graaf, Marlies, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Spekhorst, Lotte S, Boesjes, Celeste M, Loman, Laura, Zuithoff, Nicolaas P A, Bakker, Daphne S, Kamphuis, Esmé, Kamsteeg, Marijke, Haeck, Inge, Oosting, Albert J, van Lumig, Paula P M, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Flinterman, Annebeth, Garritsen, Floor M, Touwslager, Wouter R H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, and de Graaf, Marlies

Published
2023

27. The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Spekhorst, Lotte S, de Graaf, Marlies, van der Rijst, Lisa P, Zuithoff, Nicolaas P A, Schweizer, René C, Kamsteeg, Marijke, Haeck, Inge, van Lynden-van Nes, Anneke M T, van Lumig, Paula, Romeijn, Geertruida L E, Schuttelaar, Marie-Louise, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Spekhorst, Lotte S, de Graaf, Marlies, van der Rijst, Lisa P, Zuithoff, Nicolaas P A, Schweizer, René C, Kamsteeg, Marijke, Haeck, Inge, van Lynden-van Nes, Anneke M T, van Lumig, Paula, Romeijn, Geertruida L E, Schuttelaar, Marie-Louise, and de Bruin-Weller, Marjolein S

Published
2023

28. Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Boesjes, Celeste M, van Emst, Madelon, Bakker, Daphne S, Spekhorst, Lotte S, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Boesjes, Celeste M, van Emst, Madelon, Bakker, Daphne S, Spekhorst, Lotte S, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein S

Published
2023

29. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Boesjes, Celeste M, Van der Gang, Liana F, Zuithoff, Nicolaas P A, Bakker, Daphne S, Spekhorst, Lotte S, Haeck, Inge, Kamsteeg, Marijke, De Graaf, Marlies, De Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Boesjes, Celeste M, Van der Gang, Liana F, Zuithoff, Nicolaas P A, Bakker, Daphne S, Spekhorst, Lotte S, Haeck, Inge, Kamsteeg, Marijke, De Graaf, Marlies, and De Bruin-Weller, Marjolein S

Published
2023

30. A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis

Author

MS MDL 1, Cancer, Infection & Immunity, MS Dermatologie/Allergologie, MS Reumatologie/Immunologie/Infectie, van de Meeberg, Maartje M., Hebing, Renske C.F., Nurmohamed, Michael T., Fidder, Herma H., Heymans, Martijn W., Bouma, Gerd, de Bruin-Weller, Marjolein S., Tekstra, Janneke, van den Bemt, Bart, de Jonge, Robert, Bulatović Ćalasan, Maja, MS MDL 1, Cancer, Infection & Immunity, MS Dermatologie/Allergologie, MS Reumatologie/Immunologie/Infectie, van de Meeberg, Maartje M., Hebing, Renske C.F., Nurmohamed, Michael T., Fidder, Herma H., Heymans, Martijn W., Bouma, Gerd, de Bruin-Weller, Marjolein S., Tekstra, Janneke, van den Bemt, Bart, de Jonge, Robert, and Bulatović Ćalasan, Maja

Published
2023

31. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Spekhorst, Lotte S, van der Rijst, Lisa P, de Graaf, Marlies, van Megen, Maxime, Zuithoff, Nicolaas P A, Knulst, André C, de Bruin-Weller, Marjolein S, Le, Thuy-My, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Spekhorst, Lotte S, van der Rijst, Lisa P, de Graaf, Marlies, van Megen, Maxime, Zuithoff, Nicolaas P A, Knulst, André C, de Bruin-Weller, Marjolein S, and Le, Thuy-My

Published
2023

32. Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation.

Author

Boesjes, Celeste M., Bakker, Daphne S., Knol, Edward F., de Graaf, Marlies, van Wijk, Femke, and de Bruin‐Weller, Marjolein S.

Subjects
BIOTHERAPY, INFLAMMATION, ECZEMA
Abstract

This article discusses the use of thymus and activation-regulated chemokine (TARC) as a biomarker for atopic dermatitis (AD) patients undergoing different treatments. The study found that AD patients treated with Janus kinase (JAK) inhibitors had persistently high or increased serum TARC levels despite clinical improvement, raising questions about the reliability of TARC as a biomarker in these patients. In contrast, patients treated with biological therapies such as dupilumab or tralokinumab showed a substantial decrease in serum TARC levels. The authors suggest that further research is needed to understand the underlying mechanisms and evaluate the safety of JAK inhibitors. [Extracted from the article]

Published
2024
Full Text
View/download PDF

34. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Author

Boesjes, Celeste M., primary, Van der Gang, Liana F., additional, Zuithoff, Nicolaas P.A., additional, Bakker, Daphne S., additional, Spekhorst, Lotte S., additional, Haeck, Inge, additional, Kamsteeg, Marijke, additional, De Graaf, Marlies, additional, and De Bruin-Weller, Marjolein S., additional

Published
2023
Full Text
View/download PDF

36. The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, van der Rijst, Lisa P., additional, Zuithoff, Nicolaas P. A., additional, Schweizer, René C., additional, Kamsteeg, Marijke, additional, Haeck, Inge, additional, van Lynden‐van Nes, Anneke M. T., additional, van Lumig, Paula, additional, Romeijn, Geertruida L. E., additional, Schuttelaar, Marie‐Louise, additional, and de Bruin‐Weller, Marjolein S., additional

Published
2023
Full Text
View/download PDF

38. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, Loeff, Floris, additional, Zuithoff, Nicolaas P. A., additional, Bakker, Daphne, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Achten, Roselie, additional, van Wijk, Femke, additional, Rispens, Theo, additional, and de Bruin-Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

39. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

Author

Kamphuis, Esmé, primary, Boesjes, Celeste M., additional, Loman, Laura, additional, Bakker, Daphne S., additional, Poelhekken, Mila, additional, Zuithoff, Nicolaas P. A., additional, Kamsteeg, Marijke, additional, Romeijn, Geertruida L. E., additional, van Wijk, Femke, additional, de Bruin‐Weller, Marjolein S., additional, de Graaf, Marlies, additional, and Schuttelaar, Marie L. A., additional

Published
2022
Full Text
View/download PDF

42. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Author

Boesjes, Celeste M., primary, Kamphuis, Esmé, additional, Zuithoff, Nicolaas P.A., additional, Bakker, Daphne S., additional, Loman, Laura, additional, Spekhorst, Lotte S., additional, Haeck, Inge, additional, Kamsteeg, Marijke, additional, Van Lynden-van Nes, Anneke M.T., additional, Garritsen, Floor M., additional, Politiek, Klaziena, additional, Oldhoff, Marja, additional, De Graaf, Marlies, additional, Schuttelaar, Marie L.A., additional, and De Bruin-Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

43. A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis

Author

van de Meeberg, Maartje M., primary, Hebing, Renske C. F., additional, Nurmohamed, Michael T., additional, Fidder, Herma H., additional, Heymans, Martijn W., additional, Bouma, Gerd, additional, de Bruin‐Weller, Marjolein S., additional, Tekstra, Janneke, additional, van den Bemt, Bart, additional, de Jonge, Robert, additional, and Bulatović Ćalasan, Maja, additional

Published
2022
Full Text
View/download PDF

44. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry

Author

Paller, Amy S., primary, Guttman-Yassky, Emma, additional, Schuttelaar, Marie L.A., additional, Irvine, Alan D., additional, Baselga, Eulalia, additional, Kataoka, Yoko, additional, Antila, Martti, additional, de Bruin-Weller, Marjolein S., additional, Marcoux, Danielle, additional, Abramova, Alvina, additional, Rizova, Elena, additional, Liu, Chunyuan, additional, and Zhang, Annie, additional

Published
2022
Full Text
View/download PDF

45. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, Zuithoff, Nicolaas P. A., additional, van den Reek, Juul M. P. A., additional, Kamsteeg, Marijke, additional, Boesjes, Celeste M., additional, Romeijn, Geertruida L. E., additional, Loman, Laura, additional, Haeck, Inge, additional, Oosting, Albert J., additional, de Boer-Brand, Astrid, additional, Touwslager, Wouter R. H., additional, Flinterman, Annebeth, additional, van Lynden-van Nes, Anneke M. T., additional, Gostynski, Antoni H., additional, de Bruin-Weller, Marjolein S., additional, and Schuttelaar, Marie-Louise, additional

Published
2022
Full Text
View/download PDF

47. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

Spekhorst, Lotte S., primary, Bakker, Daphne, additional, Drylewicz, Julia, additional, Rispens, Theo, additional, Loeff, Floris, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Romeijn, Geertruida L. E., additional, Loman, Laura, additional, Schuttelaar, Marie‐Louise, additional, van Wijk, Femke, additional, de Graaf, Marlies, additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

48. Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry

Author

van der Schoot, Lara S., primary, Groenewoud, Hans J. M. M., additional, van Gelder, Marleen M. H. J., additional, Otero, Marisol E., additional, Arnold, W. Peter, additional, Berends, Maartje A. M., additional, De Bruin‐Weller, Marjolein S., additional, Dodemont, Sharon R. P., additional, Kleinpenning, Marloes M., additional, Koetsier, Marjolein I. A., additional, Kop, Else N., additional, Körver, John E. M., additional, Kuijpers, Astrid L. A., additional, van Lümig, Paula P., additional, Mommers, Johannes M., additional, Njoo, Marcellus D., additional, Ossenkoppele, Paul M., additional, Tupker, Ron A., additional, Visch, M. Birgitte, additional, Weppner‐Parren, Lizelotte J. M. T., additional, de Jong, Elke M. G. J., additional, and van den Reek, Juul M. P. A., additional

Published
2022
Full Text
View/download PDF

49. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

Author

Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie-Louise

Abstract

Importance: Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. Furthermore, little is known about the factors associated with drug survival of dupilumab in AD.Objective: To describe the drug survival of dupilumab in patients with AD and to identify associated predictors.Design, Setting, and Participants: This cohort study was based on data from the multicenter prospective daily practice BioDay registry, in which 4 university and 10 nonuniversity hospitals in the Netherlands participated. Analysis included patients (age ≥18 years) participating in the BioDay registry with a follow-up of at least 4 weeks. The first patient treated with dupilumab was recorded in the BioDay registry in October 2017; data lock took place in December 2020, and data analysis was performed from October 2017 to December 2020.Main Outcomes and Measures: Drug survival was analyzed by Kaplan-Meier survival curves and associated characteristics by using univariate and multivariate Cox regression analysis.Results: A total of 715 adult patients with AD (mean [SD] age, 41.8 [16.0] years; 418 [58.5%] were male) were included with a 1-year, 2-year, and 3-year overall dupilumab drug survival of 90.3%, 85.9%, and 78.6%, respectively. Characteristics associated with shorter drug survival owing to ineffectiveness were the use of immunosuppressant drugs at baseline (hazard ratio [HR], 2.64; 95% CI, 1.10-6.37) and being a nonresponder at 4 weeks (HR, 8.68; 95% CI, 2.97-25.35). Characteristics associated with shorter drug survival owing to adverse effects were the use of immunosuppressant drugs at baseline (HR, 2.69; 95% CI, 1.32-5.48), age 65 years or older (HR, 2.94; 95% CI, 1.10-7.87), and Investigator Global Assessment score of very severe AD (HR, 3.51; 95% CI, 1.20-10.28).Conclusions and Relevance: This cohort study demonstrated a good overall 1-year, 2-year, and 3-year dupilumab drug survival. Patients using immunosuppres

Published
2022

50. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry

Author

Infection & Immunity, MS Dermatologie/Allergologie, Oosterhaven, Jart A F, Spekhorst, Lotte S, Zhang, Junfen, Voorberg, Angelique N, Romeijn, Geertruida L E, Boesjes, Celeste M, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Schuttelaar, Marie L A, Infection & Immunity, MS Dermatologie/Allergologie, Oosterhaven, Jart A F, Spekhorst, Lotte S, Zhang, Junfen, Voorberg, Angelique N, Romeijn, Geertruida L E, Boesjes, Celeste M, de Graaf, Marlies, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie L A

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results